Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Common Equity (2021 - 2025)

Stoke Therapeutics has reported Common Equity over the past 5 years, most recently at $352.5 million for Q4 2025.

  • For Q4 2025, Common Equity rose 53.9% year-over-year to $352.5 million; the TTM value through Dec 2025 reached $352.5 million, up 53.9%, while the annual FY2025 figure was $352.5 million, 53.9% up from the prior year.
  • Common Equity for Q4 2025 was $352.5 million at Stoke Therapeutics, up from $308.1 million in the prior quarter.
  • Over five years, Common Equity peaked at $352.5 million in Q4 2025 and troughed at $140.3 million in Q1 2024.
  • A 5-year average of $235.1 million and a median of $224.3 million in 2022 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: tumbled 34.37% in 2024 and later skyrocketed 149.44% in 2025.
  • Year by year, Common Equity stood at $217.8 million in 2021, then fell by 15.12% to $184.8 million in 2022, then fell by 13.68% to $159.6 million in 2023, then skyrocketed by 43.53% to $229.0 million in 2024, then skyrocketed by 53.9% to $352.5 million in 2025.
  • Business Quant data shows Common Equity for STOK at $352.5 million in Q4 2025, $308.1 million in Q3 2025, and $334.9 million in Q2 2025.